10 of 15 perpetual futures on Binance are TradFi perpetuals ranging from equities to commodities
ISLAMABAD, Aug. 25, 2026 /PRNewswire/ -- Binance's push to bring traditional finance (TradFi) assets onto its crypto-native platform is showing clear signs of traction, according to real-time derivatives data. A snapshot of the top 15 perpetual contracts on Binance by 24-hour volume shows that roughly two-thirds are now linked to traditional assets (equities, ETFs, and commodities) with the crypto perpetuals led by BTC, ETH and SOL.
The top 15 list is led by SANDUSDT (SanDisk) perpetual contract with ~$6.87 bn 24-hour trading volume on Binance as of 19 August, 9:00am UTC. This was approximately 22% of the 24-hour SanDisk trading volume on Nasdaq.[1]
The other top perpetual contracts by current trading volume includes other single-name equities, equity-linked products, and commodity contracts such as XAGUSDT (Silver) (~$826 mil trading vol on Binance), alongside established crypto perps.
"The shift validates Binance's stated mission to make its platform a multi-asset financial super app where users can access crypto and traditional asset classes within a single account. By offering USDT-margined perpetual contracts on ETFs, commodities and more, Binance has effectively extended crypto-style round-the-clock trading to assets that were previously confined to traditional market hours," said Shunyet Jan, Head of Exchange and Trading at Binance.
Recent industry data supports this trend. Weekly stock-linked perpetual volume on centralized exchanges has surged roughly 79x since the start of 2026, with Binance identified as the dominant venue for equity perps. In July alone, Binance accounted for about 76% of equity perpetual volume across tracked exchanges, highlighting its central role in the convergence of crypto and TradFi trading.
Disclaimer: Products and services referred to here may not be available in your region. Digital asset prices can be volatile. The value of your investment may go down or up and you may not get back the amount invested. You are solely responsible for your investment decisions and Binance is not liable for any losses you may incur. TradFi Perps are subject to high market risk and price volatility (particularly outside traditional market hours). You may be called upon at short notice to make additional margin deposits or interest payments. If the required margin deposits or interest payments are not made within the prescribed time, your collateral may be liquidated. Moreover, you will remain liable for any resulting deficit in your account and interest charged on your account. All of your margin balance may be liquidated in the event of adverse price movement. Past performance is not a reliable predictor of future performance. TradFi Perps do not represent ownership of the relevant underlying asset. Before trading, you should make an independent assessment of the appropriateness of the transaction in light of your own objectives and circumstances, including the risks and potential benefits. Consult your own advisers, where appropriate. This information should not be construed as financial or investment advice. TradFi Perps are not associated or affiliated with, or sponsored or endorsed by, the issuer of the relevant underlying shares or the exchange on which they are listed. Futures trading is restricted in certain countries and to certain users. This content is not intended for users/countries to which restrictions apply. To learn more about how to protect yourself, visit our Responsible Trading page. For more information, see our Terms of Use, Clearing Rules, Clearing Procedures, Contract Specifications and Risk Warning.
About Binance
Binance is a leading global blockchain ecosystem behind the world's largest cryptocurrency exchange by trading volume and registered users. Binance is trusted by more than 320 million people in 100+ countries for its industry-leading security, transparency, trading engine speed, protections for investors, and unmatched portfolio of digital asset products and offerings from trading and finance to education, research, social good, payments, institutional services, and Web3 features. Binance is devoted to building an inclusive crypto ecosystem to increase the freedom of money and financial access for people around the world with crypto as the fundamental means. For more information, visit: https://www.binance.com.
[1] This is an approximation of Nasdaq SNDK trading volume. Nasdaq provides data for share volume, the approximation of dollar volume is based on shares × price https://www.nasdaq.com/market-activity/stocks/sndk/historical
https://nasdaqtrader.com/Trader.aspx?id=DailyMarketSummaryDefs
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Binance TradFi Perpetuals Gain Greater Traction as Multi-Asset Strategy Takes Hold
- Expands global portfolio beyond HIFU and MRF to include MNRF, laser, and dermabrasion devices, strengthening its medium- to long-term growth foundation
- 1H26 Exports, excluding shipments to its Brazilian subsidiary, grew 29% year over year, underscoring continued growth across global markets
SEOUL, South Korea, Aug. 25, 2026 /PRNewswire/ -- Classys Inc. (KOSDAQ: 214150), a global medical aesthetics company, announced today that, supported by its robust global commercial infrastructure, it expects device sales worldwide to surpass 50,000 units this year.
This milestone reflects the company's successful expansion into new device categories, including microneedle radiofrequency (MNRF) and laser systems, beyond its traditional core portfolio of high-intensity focused ultrasound (HIFU) and monopolar radiofrequency (MRF). By offering a comprehensive aesthetic portfolio designed to address diverse customer needs and leveraging its large global installed base, Classys is strengthening the foundation for sustainable medium- to long-term growth.
As of the end of June, Classys had a cumulative global installed base of more than 22,000 units for its flagship HIFU line and more than 4,000 units for its MRF line. Its MNRF and dermabrasion product lines have also each surpassed 6,000 cumulative global installations. Classys plans to leverage this established footprint to introduce next-generation platforms and create additional avenues for growth through the global rollout of Quadessy and the planned European launch of Viclara later this year.
A well-established sales infrastructure underpins this global expansion. The domestic Korean market, which accounts for approximately 25% of total revenue, serves as a key test market for validating new products and clinical treatment protocols while strengthening the company's global brand competitiveness. Internationally, Classys has established end-to-end commercial capabilities—from initial market entry and product launches to procedure adoption—supported by a global distributor network, key opinion leaders (KOLs), and a broad network of clinic customers. The ability to introduce next-generation devices through this existing distribution infrastructure is expected to serve as a key driver of future growth.
This expanding commercial foundation continues to translate into strong financial performance. Classys reported consolidated revenue of KRW 192.7 billion for the first half of the year, representing a 20% year-over-year increase. Even excluding the impact of consolidating its Brazilian subsidiary, growth across existing international markets remained robust. Excluding shipments from Classys headquarters to its Brazilian subsidiary, 1H26 export sales increased 29% year over year, demonstrating that demand for Classys products continues to grow across its existing global markets beyond the impact of the transition to direct sales in Brazil.
In Europe, market diversification delivered tangible results, driven by expansion into new countries—including the UK, Sweden, the Netherlands, Finland, Hungary, and Bulgaria—as well as sales growth in existing European markets. Despite continued investments in global commercialization and market expansion, Classys maintained strong profitability, achieving a standalone operating margin of 50.8% in the first half of the year.
The expansion of the installed base is also significant, as it supports recurring consumables revenue and the adoption of multi-device combination treatments. In the first half of the year, consumables revenue reached KRW 80.2 billion, up 5.3% year over year and 52.7% from the first half of 2024. As cumulative global device installations continue to grow, the foundation for stable, recurring consumables revenue is expanding accordingly.
Portfolio diversification through new products is also accelerating, particularly in the dermabrasion category. The previous-generation Aquapure has already built a track record of global sales and established customer relationships, helping to lower barriers to market entry. Set to launch in Europe under the brand name "Viclara" by the end of this year, Classys plans to drive cross-selling and increase utilization by leveraging its existing HIFU, MRF, and MNRF customer base and global distribution network.
Moving forward, Classys plans to expand device distribution in line with regional regulatory approvals and launch timelines, while introducing combination treatment protocols to existing customers to increase device utilization and revenue per customer. The company will also intensify localized marketing efforts through global medical congresses, clinical education programs, and KOL collaborations tailored to regional skin characteristics, treatment preferences, and practitioner needs.
"The continued growth in cumulative global device sales demonstrates that Classys is steadily expanding its reach among medical professionals and patients worldwide," said Yugene Choi, Head of Investor Relations at Classys. "By continuously introducing new platforms and clinical treatment protocols to our established installed base, distribution channels, and clinical networks, we aim to drive continued growth in both device and consumables sales and sustain our long-term growth in the global medical aesthetics market."
SEOUL, South Korea, Aug. 25, 2026 /PRNewswire/ -- Classys Inc. (KOSDAQ: 214150), a global medical aesthetics company, announced today that, supported by its robust global commercial infrastructure, it expects device sales worldwide to surpass 50,000 units this year.
This milestone reflects the company's successful expansion into new device categories, including microneedle radiofrequency (MNRF) and laser systems, beyond its traditional core portfolio of high-intensity focused ultrasound (HIFU) and monopolar radiofrequency (MRF). By offering a comprehensive aesthetic portfolio designed to address diverse customer needs and leveraging its large global installed base, Classys is strengthening the foundation for sustainable medium- to long-term growth.
As of the end of June, Classys had a cumulative global installed base of more than 22,000 units for its flagship HIFU line and more than 4,000 units for its MRF line. Its MNRF and dermabrasion product lines have also each surpassed 6,000 cumulative global installations. Classys plans to leverage this established footprint to introduce next-generation platforms and create additional avenues for growth through the global rollout of Quadessy and the planned European launch of Viclara later this year.
A well-established sales infrastructure underpins this global expansion. The domestic Korean market, which accounts for approximately 25% of total revenue, serves as a key test market for validating new products and clinical treatment protocols while strengthening the company's global brand competitiveness. Internationally, Classys has established end-to-end commercial capabilities—from initial market entry and product launches to procedure adoption—supported by a global distributor network, key opinion leaders (KOLs), and a broad network of clinic customers. The ability to introduce next-generation devices through this existing distribution infrastructure is expected to serve as a key driver of future growth.
This expanding commercial foundation continues to translate into strong financial performance. Classys reported consolidated revenue of KRW 192.7 billion for the first half of the year, representing a 20% year-over-year increase. Even excluding the impact of consolidating its Brazilian subsidiary, growth across existing international markets remained robust. Excluding shipments from Classys headquarters to its Brazilian subsidiary, 1H26 export sales increased 29% year over year, demonstrating that demand for Classys products continues to grow across its existing global markets beyond the impact of the transition to direct sales in Brazil.
In Europe, market diversification delivered tangible results, driven by expansion into new countries—including the UK, Sweden, the Netherlands, Finland, Hungary, and Bulgaria—as well as sales growth in existing European markets. Despite continued investments in global commercialization and market expansion, Classys maintained strong profitability, achieving a standalone operating margin of 50.8% in the first half of the year.
The expansion of the installed base is also significant, as it supports recurring consumables revenue and the adoption of multi-device combination treatments. In the first half of the year, consumables revenue reached KRW 80.2 billion, up 5.3% year over year and 52.7% from the first half of 2024. As cumulative global device installations continue to grow, the foundation for stable, recurring consumables revenue is expanding accordingly.
Portfolio diversification through new products is also accelerating, particularly in the dermabrasion category. The previous-generation Aquapure has already built a track record of global sales and established customer relationships, helping to lower barriers to market entry. Set to launch in Europe under the brand name "Viclara" by the end of this year, Classys plans to drive cross-selling and increase utilization by leveraging its existing HIFU, MRF, and MNRF customer base and global distribution network.
Moving forward, Classys plans to expand device distribution in line with regional regulatory approvals and launch timelines, while introducing combination treatment protocols to existing customers to increase device utilization and revenue per customer. The company will also intensify localized marketing efforts through global medical congresses, clinical education programs, and KOL collaborations tailored to regional skin characteristics, treatment preferences, and practitioner needs.
"The continued growth in cumulative global device sales demonstrates that Classys is steadily expanding its reach among medical professionals and patients worldwide," said Yugene Choi, Head of Investor Relations at Classys. "By continuously introducing new platforms and clinical treatment protocols to our established installed base, distribution channels, and clinical networks, we aim to drive continued growth in both device and consumables sales and sustain our long-term growth in the global medical aesthetics market."
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Classys Nears 50,000 Devices Sold Globally as Full-Lineup Growth Accelerates
